drugset / Trial / NCT02266927
A Study to Compare the Bioavailability Intranasal Administration of 200 and 400 µg or 400 µg Alone of OPTINOSE™ FLUTICASONE With 440 µg of Flovent® HFA (Fluticasone Propionate) Inhalation Aerosol (Part 2)
RandomizedCrossoverOpen-labelTreatment
Summary
To compare the systemic exposure of a single dose of 400 µg of OPTINOSE FLUTICASONE with 440 µg of Flovent® HFA (fluticasone propionate) Inhalation Aerosol in asthmatic subjects.
Timeline
- Start
- 2014-09
- Primary completion
- 2015-03
- Completion
- 2015-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fluticasone propionate | Other / unclassified | 400 ug | Intranasal |
| Comparator | Fluticasone propionate | Other / unclassified | 440 ug | Intranasal |
| Comparator | Fluticasone propionate | Other / unclassified | 440 ug | Inhaled |